Product Information
FUROSEMIDE 40 MG/4 ML VIAL is a generic product labeled by Devatis Inc., priced at $0.2525 per ML under NDC 73043002301. Its NADAC has been published 77 times since Apr 16, 2025.
FDA first approved this application on Apr 2, 2024. Its Orange Book therapeutic-equivalence code is AP.
Strength
10 mg/mL
Manufacturer
Devatis Inc.NDC
73043002301
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
FUROSEMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215856FDA Approved
4/2/2024
TE Code
AP
On Market Since
8/10/2024
Pharmacological Classes
Price Statistics
The NADAC for FUROSEMIDE 40 MG/4 ML VIAL has been published 77 times since Apr 16, 2025, and over the history we have for it it has risen 10.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2525 per ML |
|---|---|
| All-time high | $0.3500 (May 13, 2026) |
| All-time low | $0.2231 (Jun 18, 2025) |
| 52-week high | $0.3500 |
| 52-week low | $0.2231 |
| Median price | $0.2263 |
| Average price | $0.2627 |
| Largest weekly change | +47.3% (Feb 18, 2026) |
| Weeks tracked | 77 |
| Tracking since | Apr 16, 2025 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Devatis Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
furosemide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FUROSEMIDE 40 MG/4 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for FUROSEMIDE 40 MG/4 ML VIAL, manufactured by Devatis Inc., is $0.2525 per ML (NDC 73043002301), effective Sep 30, 2026.
How has the price of FUROSEMIDE 40 MG/4 ML VIAL changed over time?
Over the history we have for it, the NADAC for FUROSEMIDE 40 MG/4 ML VIAL has risen 10.0%. It has been tracked across 77 weekly CMS publications since Apr 16, 2025.
What are the highest and lowest recorded NADAC prices for FUROSEMIDE 40 MG/4 ML VIAL?
Since Apr 16, 2025, the NADAC for FUROSEMIDE 40 MG/4 ML VIAL has ranged from a low of $0.2231 (Jun 18, 2025) to a high of $0.3500 (May 13, 2026), with a median of $0.2263 per ML.
Are there cheaper alternatives to FUROSEMIDE 40 MG/4 ML VIAL?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FUROSEMIDE 40 MG/4 ML VIAL, is $0.2334 per ML — about 8% below FUROSEMIDE 40 MG/4 ML VIAL.
Who manufactures FUROSEMIDE 40 MG/4 ML VIAL?
FUROSEMIDE 40 MG/4 ML VIAL (NDC 73043002301) is labeled by Devatis Inc., and CMS classifies it as a generic product.